Clinical trial
Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent…
NCT00445588 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00445588 |
|---|---|
| Title | Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme |
| Official title | A Phase II Trial of Erlotinib (OSI-774) and Sorafenib (BAY 43-9006) for Patients With Progression or Recurrent Glioblastoma Multiforme |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor |
| Intervention type | Drug, Other |
| Interventions | erlotinib hydrochloride, sorafenib tosylate, pharmacological study |
| Enrollment | 56 |
| Start date | Jan 1, 2007 |
| Primary completion | Aug 1, 2009 |
| Completion | Aug 1, 2009 |
| First posted | Mar 9, 2007 |
| Last update posted | Apr 27, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: